PROVIDER PROFILE · NPI 1013990506

Rowena SistasisM.D.

PRACTICESISTASIS FAMILY PRACTICE,INC.See all providers at this practice →

Family PracticeAsheboro, NCI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

Unique beneficiaries

—

Total services

130

Distinct HCPCS

Medicare payment

$8K

Peer benchmark

Total Medicare services vs. 2,740 Family Practice providers in NC — bottom quintile (cohort median 664).

PRESCRIBING · PART D · 2024

Total Rx claims

3,250

Beneficiaries

—

Total drug cost

$282K

Distinct drugs

Brand share

17.8%

Top prescribed drugs

Amlodipine Besylate190 claims

Atorvastatin Calcium161 claims

Lisinopril154 claims

Levothyroxine Sodium141 claims

Montelukast Sodium122 claims

QUALITY · MIPS · 2024

No data available for this provider in 2024.

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

Total received

$119

Payment records

By payment type

Food and Beverage$119

Top paying entities

Food and Beverage$119

FACILITY AFFILIATIONS

Hospital & Facility Affiliations (1)

CCN 340123

Hospital

REFERRAL NETWORK

Where Rowena Sistasis's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 2 inbound referrers · 3 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
SOLSTAS LAB PARTNERS GROUP LLC	14	30
RANDOLPH HOSPITAL INC.	11	47

Refers patients to

Outbound — where patients go next

Physician	Patients	Visits
SOLSTAS LAB PARTNERS GROUP LLC	31	97
Laboratory Corporation Of America Holdings Clinical Laboratory · Burlington, NC	23	63
RANDOLPH HOSPITAL INC.	21	106

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history